KRAS and colorectal carcinoma: Our analysis identified three upregulated gene sets (see Table 2) for which the average differential expression between CRC and non-lesional tissues was significantly more pronounced in KRAS-mutated tumors (ANOVA interaction p < 0.05, Table 2).